RTP Mobile Logo
Oncology Today with Dr Neil Love: Management of Gastroesophageal Cancers (Audio Interview)
Released January 2023

Featuring an interview with Dr Manish Shah. Published January 12, 2023. (Audio Interview)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastroesophageal cancers.

    LEARNING OBJECTIVES

    • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to personalize the selection of first-line therapy for patients with locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
    • Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for the management of gastric, GEJ and esophageal cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
    • Optimally incorporate available therapeutic agents and regimens into the management of HER2-negative metastatic gastric, GEJ and esophageal cancer that has progressed on front-line therapy.
    • Appraise clinical trial findings supporting the use of adjuvant anti-PD-1 antibody therapy in patients with resected esophageal/GEJ cancer who have received neoadjuvant chemoradiation therapy and have residual pathologic disease, and discern the clinical applicability of this treatment strategy.
    • Recall available data with novel HER2-targeted agents and strategies for patients with newly diagnosed and previously treated HER2-overexpressing gastric/GEJ cancer, and optimally identify candidates who may be appropriate for these approaches.
    • Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
    • Review the rationale for, available data with and ongoing research studies evaluating novel agents and strategies for patients with gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible individuals.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Presentations Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Manish A Shah, MD
    Chief, Solid Tumor Oncology Service
    Director, Gastrointestinal Oncology Program
    Co-Director, Center for Advanced Digestive Care
    Bartlett Family Professor of Gastrointestinal Oncology
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
    New York, New York

    No relevant conflicts of interest to disclose.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Elevation Oncology Inc.

    Release date: January 2023
    Expiration date: January 2024

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):